<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00461604</url>
  </required_header>
  <id_info>
    <org_study_id>1690/07</org_study_id>
    <nct_id>NCT00461604</nct_id>
  </id_info>
  <brief_title>High Dosage Esomeprazole and Baclofen for Therapy of Gastroesophageal Reflux Disease</brief_title>
  <acronym>NEXBAC</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>Technical University of Munich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Technical University of Munich</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      It has been reported that Baclofen is an appropriate tool in the therapeutic management of&#xD;
      Gastroesophageal Reflux Disease. To objectify gastroesophageal reflux combined&#xD;
      pH-metry/impedance monitoring was applied to patients with persistent reflux-associated&#xD;
      symptoms despite PPI-therapy (40mg esomeprazole for 2 weeks). After provement of pathological&#xD;
      findings in the test PPI-dosage was escalated to double standard-dosage for another for&#xD;
      weeks. In case of persistent symptoms another ph-metry/impedance monitoring was performed. In&#xD;
      case of pathological findings additional baclofen was administered to the therapeutic regime.&#xD;
      After 3 months another ph-metry/impedance monitoring was performed. At the time point of the&#xD;
      tests a questionnaire was completed.&#xD;
&#xD;
      Aim of the study was to evaluate the influence of high dosage PPI-therapy and additional&#xD;
      baclofen in patients with persistent symptoms and objectified gastroesophageal reflux.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2006</start_date>
  <completion_date type="Actual">May 2008</completion_date>
  <primary_completion_date type="Actual">May 2008</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Patients With Persistent Objectified Gastroesophageal Reflux and Reflux-Associated Symptoms Despite PPI-Therapy With 40mg Esomeprazole</condition>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  age between 18-70 years&#xD;
&#xD;
          -  informed consent&#xD;
&#xD;
          -  patients with persistent reflux-associated symptoms despite PPI-therapy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  epilepsy&#xD;
&#xD;
          -  synthetic liver diseases&#xD;
&#xD;
          -  renal failure&#xD;
&#xD;
          -  disability to understand informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexander Meining, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Technische University Munich</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Technical University of Munich</name>
      <address>
        <city>Munich</city>
        <state>Bavaria</state>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2008</verification_date>
  <study_first_submitted>April 16, 2007</study_first_submitted>
  <study_first_submitted_qc>April 16, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 18, 2007</study_first_posted>
  <last_update_submitted>May 19, 2008</last_update_submitted>
  <last_update_submitted_qc>May 19, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 20, 2008</last_update_posted>
  <responsible_party>
    <name_title>Technische Universit채t M체nchen, II. Medizinische Klinik</name_title>
    <organization>Technische Universit채t M체nchen</organization>
  </responsible_party>
  <keyword>gastroesophageal reflux disease</keyword>
  <keyword>baclofen</keyword>
  <keyword>impedance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastroesophageal Reflux</mesh_term>
    <mesh_term>Esophagitis, Peptic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

